Thermo Fisher Scientific Inc. Earnings Recaps
Q2 2026
Jul 25, 2026
Thermo Fisher shares rose 7.9% following a quarter that beat expectations on revenue growth, margin expansion, and innovation-driven execution across key end markets.
Key takeaways
- Revenue increased 10% to $11.99 billion, driven by broad strength across Pharma & Biotech, Academic & Government, Industrial & Applied, and Diagnostics & Health Care segments.
- Adjusted operating income grew 15% to $2.73 billion, with operating margins expanding by 90 basis points to 22.8%.
- Adjusted EPS rose 13% to $6.03 per share, reflecting both top-line strength and margin leverage.
- Continued high-impact innovation including new Orbitrap mass spectrometry platforms and AI-enhanced software contributed to commercial momentum and customer adoption.
- Strategic investments such as opening a bioprocess design center and collaboration in population health research underscore ongoing commitments to growth and customer engagement.
Q1 2026
Apr 23, 2026
Thermo Fisher delivered a robust Q1 with 6% revenue growth to $11.01 billion, driven by strength in biotech and pharma markets, while maintaining disciplined margins and expanding innovative offerings.
Key takeaways
- Revenue increased 6% to $11.01 billion; adjusted EPS up 6% to $5.44, supported by a 21.8% operating margin.
- Pharma and biotech markets grew mid-single-digit, led by bioproduction, clinical research, and safety channels.
- Launches included advanced cryo-EM and mass spectrometry solutions, reinforcing industry leadership and customer value.
- Strategic collaborations with NVIDIA and SHL Medical enhance AI-driven workflows and manufacturing capabilities.
- End markets are expected to remain resilient amid macroeconomic uncertainties and ongoing innovation efforts.
Q3 2025
Oct 22, 2025
Thermo Fisher Scientific demonstrated solid operational performance in Q3 2025, achieving a 5% revenue increase to $11.12 billion and raising full-year guidance due to strong growth in its bioproduction and analytical instruments segments.
Key takeaways
- Adjusted operating income rose 9% to $2.59 billion, while adjusted EPS grew 10% to $5.79 per share.
- Pharma and biotech revenue maintained mid-single-digit growth, supported by strong contributions from bioproduction and analytical instruments.
- Diagnostics and Healthcare revenue showed improvement, though it remained down low single digits due to challenging conditions in China.
- Continued innovation highlighted by FDA approvals for clinical genomic tests and new launches in proteomics and electron microscopy.
- Strengthened customer relationships through strategic collaborations, including a notable partnership with OpenAI.